← back to search

Lifang Li

Shenzhen Second People's Hospital · CN
Area of research
Molecular Biology · Physical Therapy, Sports Therapy and Rehabilitation
Research interest
Research interests include CRISPR and Genetic Engineering, Balance, Gait, and Falls Prevention, Plant Virus Research Studies, and Apelin-related biomedical research.
h-index
16
citations
1,159
works
57
NIH funding
primary concept
email

Recent publications

Fascin Inhibitor NP-G2-044 Decreases Cell Metastasis while Increases Overall Survival of Mice-bearing Lung Cancers
Current Molecular Medicine 2024cited by 3position: middledoi
Association between triglyceride-glucose index and sarcopenia in patients with chronic inflammatory airway disease
Heliyon 2024cited by 2position: middledoi
HPV integration generates a cellular super-enhancer which functions as ecDNA to regulate genome-wide transcription
Nucleic Acids Research 2023cited by 38position: middledoi
A Cas12a ortholog with distinct TTNA PAM enables sensitive detection of HPV16/18
Cell Reports Methods 2023cited by 21position: middledoi
Massively parallel CRISPR off-target detection enables rapid off-target prediction model building
Med 2023cited by 21position: middledoi
FrCas9 is a CRISPR/Cas9 system with high editing efficiency and fidelity
Nature Communications 2022cited by 41position: middledoi
Genome‐wide virus‐integration analysis reveals a common insertional mechanism of HPV, HBV and EBV
Clinical and Translational Medicine 2022cited by 29position: middledoi
Identification of Potential Active Ingredients and Mechanisms of Cattail Pollen for Treating Infertile Patients With Endometriosis Based on Bioinformatics and Molecular Docking
Natural Product Communications 2022cited by 1position: middledoi
Efficacy of the feedback teaching method on the compliance of tumor patients in preventing falls
Asian Journal of Surgery 2022cited by 1position: firstdoi
The comparison of ZFNs, TALENs, and SpCas9 by GUIDE-seq in HPV-targeted gene therapy
Molecular Therapy — Nucleic Acids 2021cited by 51position: middledoi
Gene knock-out chain reaction enables high disruption efficiency of HPV18 E6/E7 genes in cervical cancer cells
Molecular Therapy — Oncolytics 2021cited by 30position: middledoi
Vitamin E relieves chronic obstructive pulmonary disease by inhibiting COX2-mediated p-STAT3 nuclear translocation through the EGFR/MAPK signaling pathway
Laboratory Investigation 2021cited by 27position: middledoi
Association of CD4 T cell count and optimal timing of antiretroviral therapy initiation with immune reconstitution inflammatory syndrome and all-cause mortality for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis.
PubMed 2021cited by 5position: first

Grants

No grants ingested yet.

Frequent collaborators

Rui Tian · Guangdong University of Technology7 papers (2021–2023)Zheng Hu · China Pharmaceutical University7 papers (2021–2023)Jiashuo Liu · Shanghai Jiao Tong University6 papers (2021–2023)Zhuang Jin · Sun Yat-sen University6 papers (2021–2023)Zheying Huang · Fujian Medical University6 papers (2021–2023)Zhaoyue Huang · Sun Yat-sen University6 papers (2021–2023)Xun Tian · Huazhong University of Science and Technology5 papers (2021–2023)Zifeng Cui · Peking University5 papers (2021–2023) · 5 papers (2021–2023)Hongxian Xie · Guangdong Province Special Equipment Testing and Research Institute Zhuhai Testing Institute5 papers (2021–2023)Yuyan Wang · Beijing University of Chinese Medicine4 papers (2022–2023)Ye Chen · Sun Yat-sen University3 papers (2023–2023)Pingping Li · Xuchang University3 papers (2021–2024)Hui Zhao · Harbin Medical University2 papers (2021–2021)Yongfeng Hong · Anhui Medical University2 papers (2023–2023)Weiwen Fan · Sun Yat-sen University2 papers (2021–2021)Chaoyue Zhong · Wuhan University2 papers (2023–2023)Haiyan Weng · University of Science and Technology of China2 papers (2021–2022)Xing Wang · Guangzhou University of Chinese Medicine1 papers (2022–2022)Ping Zhou · China Pharmaceutical University1 papers (2021–2021)